Format

Send to

Choose Destination
Psychol Med. 2015 Oct;45(13):2793-804. doi: 10.1017/S0033291715000756. Epub 2015 May 29.

Cognitive-behavioural therapy in medication-treated adults with attention-deficit/hyperactivity disorder and co-morbid psychopathology: a randomized controlled trial using multi-level analysis.

Author information

1
Division of Brain Sciences,Department of Medicine,Centre for Mental Health,Imperial College London,London,UK.
2
King's College London,Institute of Psychiatry,Psychology and Neuroscience,London,UK.
3
Reykjavik University,Reykjavik,Iceland.
4
Broadmoor Hospital,West London Mental Health NHS Trust,Crowthorne,UK.
5
Landspitali - The National University Hospital of Iceland,Reykjavik,Iceland.

Abstract

BACKGROUND:

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by high rates of co-morbid psychopathology. Randomized controlled trials of multimodal interventions, combining pharmacological and psychological treatments, have shown a robust treatment effect for ADHD symptoms but outcomes for co-morbid symptoms have been mixed. This may be accounted for by the type of intervention selected and/or by methodological problems including lack of follow-up and low power. The current study addressed these limitations in a parallel-group randomized controlled trial conducted in Iceland.

METHOD:

A total of 95 adult ADHD patients who were already being treated with medication (MED) were randomly assigned to receive treatment as usual (TAU/MED) or 15 sessions of cognitive-behavioural therapy (CBT/MED) using the R&R2ADHD intervention which employs both group and individual modalities. Primary measures of ADHD symptoms and severity of illness, and secondary measures of anxiety, depression and quality of life were given at baseline, end of treatment and 3-month follow-up. Primary outcomes were rated by clinicians blind to treatment condition assignment.

RESULTS:

CBT/MED showed overall (combined outcome at end of treatment and 3-month follow-up) significantly greater reduction in primary outcomes for clinician-rated and self-rated ADHD symptoms. Treatment effect of primary outcomes was maintained at follow-up, which suggests robust and lasting findings. In contrast to the primary outcomes, the secondary outcomes showed significant improvement over time.

CONCLUSIONS:

The study provides evidence for the effectiveness of R&R2ADHD and demonstrates that there are differential effects over time for ADHD symptoms versus co-morbid problems, the latter taking longer to show positive effects.

KEYWORDS:

Attention-deficit/hyperactivity disorder; R & R2; cognitive–behavioural therapy; randomized controlled trials; reasoning and rehabilitation; treatment

PMID:
26022103
PMCID:
PMC4595859
DOI:
10.1017/S0033291715000756
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Cambridge University Press Icon for PubMed Central
Loading ...
Support Center